Does Legalization of Medical Marijuana Increase Illicit Use?

Summary and Comment |
May 8, 2017

Does Legalization of Medical Marijuana Increase Illicit Use?

  1. Steven Dubovsky, MD

The answer over a 20-year period in the U.S. seems to be yes.

  1. Steven Dubovsky, MD

To examine whether increases in illicit cannabis use are correlated with the passage of laws legalizing medical marijuana, researchers compared data from similar household surveys of U.S. adults conducted in three epochs over 20 years (1991–1992, 2001–2002, and 2012–2013).

The prevalence of cannabis use and cannabis use disorder (CUD) increased between the first and second surveys in states with medical marijuana laws (MMLs) at the first survey (early MML). An exception was California, the first MML state, which had a 69% higher rate of illicit cannabis use and 80% higher rate of CUD than rates in other states. Prevalences decreased in states without MMLs.

Between the second and third surveys, the percentage-point increases in prevalence of cannabis use and CUD were 3.5 and 1.0 in non-MML states, 2.6 and 0.1 in early MML states other than California and Colorado, and 5.1 and 1.7 in states that adopted MMLs after the second survey. Percentage-point increases were greater in California, with increases of 5.3 and 2.0, respectively. Another exception was Colorado, which modified its early MML law in 2009, resulting in an explosion of dispensaries. There, percentage-point increases were 7.0 and 2.7, respectively.

Comment

Over time, MML states have had higher rates of both illicit cannabis use and CUD than non-MML states. This impression is supported by the observation of sharply increased rates in Colorado after the law was changed to permit more dispensaries. California was so permissive before its MML that cannabis use did not further increase.

Another eight states have passed MMLs since the last survey. Clinicians in MML states should be alert to misuse of cannabis that, as investigators and editorialists point out, can predispose to addiction, psychosis, impaired driving, and suicidality.

Editor Disclosures at Time of Publication

  • Disclosures for Steven Dubovsky, MD at time of publication Grant / Research support Otsuka; Tower Foundation; Oshei Foundation; Patrick Lee Foundation; Wendt Foundation; Takeda; Lilly; Sumitomo; Hoffmann-La Roche; Pfizer; Neurim Pharmaceuticals; Neurocrine Biosciences Editorial boards Mind and Brain; Bulletin of the Menninger Clinic; Current Psychiatry; Journal of Psychosomatic Research

Citation(s):

Reader Comments (1)

Eric Osgood Physician, Hospital Medicine
Competing Interests: I do not believe in locking human beings in a cage for smoking a plant that has never directly caused a single death

This title is ridiculous. If it is legal, it ceases to be illicit.

And use disorder is defined as persistent use after clinical impairment, ranging from mild to severe. Did the investigators distinguish between severity? How much inter observer reliability do we assume exists between mental health professionals deciding who is mildly, moderately, or severely impaired, such that we accept observational data on such a socially important topic?

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.